Associazione Nazionale Medici Cardiologi Ospedalieri

CONGRESS ABSTRACT

CONGRESS ABSTRACT

Clinical characteristics of patients affected by heart failure patients with reduced ejection fraction and undergoing SGLT2i therapy

Alcidi Gianmarco Foggia (Foggia) – Sc Cardiologia – Aou Policlinico Di Foggia | Pugliese Rosanna Foggia (Foggia) – Sc Cardiologia – Aou Policlinico Di Foggia | Ioannoni Sara Foggia (Foggia) – Sc Cardiologia – Aou Policlinico Di Foggia | Romano Matteo Foggia (Foggia) – Sc Cardiologia – Aou Policlinico Di Foggia | Granatiero Michele Foggia (Foggia) – Sc Cardiologia – Aou Policlinico Di Foggia | Diomede Davide Foggia (Foggia) – Sc Cardiologia – Aou Policlinico Di Foggia | Benvenuto Manuela Teramo (Teramo) – Area Cardiorenale E Metabolica Anmco | Correale Michele Foggia (Foggia) – Sc Cardiologia – Aou Policlinico Di Foggia | Brunetti Natale Daniele Foggia (Foggia) – Sc Cardiologia – Aou Policlinico Di Foggia | Gronda Edoardo Milano (Milano) – Area Cardiorenale E Metabolica Anmco | Iacoviello Massimo Iacoviello Foggia (Foggia) – Sc Cardiologia – Aou Policlinico Di Foggia – Area Cardiorenale E Metabolica Anmco

Background. The type-2 sodium-glucose cotransporters inhibitors (SGLT2i) are a new relevant therapeutic option for patients affected by chronic heart failure with reduced ejection fraction (HFrEF). The aim of this study was to evaluate the clinical characteristics and therapy of HFrEF patients undergoing SGLT2i therapy.

Methods. We evaluated the consecutive patients affected by HFrEF in whom the SGLT2i therapy was prescribed since December 2021. At baseline clinical visit, ECG, echocardiography, assessment of sodium, potassium, fasting glucose, hemoglobin, hematocrit, glomerular filtration rate (GFR) by creatinine were assessed.

Results. Ninety patients were enrolled. In the Table clinical characteristics and therapy are reported. Interestingly, most of patients were already trated with the classes of drugs currently recommended fo HFrEF treatment.

 

Conclusions. In this “real world” study, SGLT2i were prescribed in HFrEF patients most of all already in therapy with the  other classes of drugs currently recommended for their treatment. These data further support the use of this therapeutic approach in routine clinical practice.